Product
CLN-619
1 clinical trial
1 indication
Indication
Advanced Solid TumorClinical trial
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-03-01